Pazopanib, sold under the brand name Votrient, is an anti-cancer medication marketed worldwide by Novartis. It is a potent and selective multi-targeted...
16 KB (1,314 words) - 05:40, 9 August 2024
and doxorubicin combination/gemcitabine and docetaxel/trabectedin; pazopanib is the targeted therapy used in metastatic leiomyosarcoma as second line...
16 KB (1,560 words) - 05:22, 3 September 2024
interferon), kinase inhibitors (temsirolimus, sunitinib, sorafenib, pazopanib) and anti-angiogenic therapies (bevacizumab). "Clear cell carcinoma"....
3 KB (333 words) - 01:07, 3 December 2023
This is a list of adverse effects of the anti-cancer drug pazopanib, sorted by frequency of occurrence. Very common (>10% incidence) adverse effects include:...
5 KB (402 words) - 17:47, 21 March 2022
progressive and locally advanced differentiated thyroid cancer (DTC). Pazopanib and axitinib are used orally for the treatment of advanced renal cell...
51 KB (4,735 words) - 08:15, 2 January 2024
tyrosine kinases stimulated by VEGF: sunitinib, sorafenib, axitinib, and pazopanib (some of these therapies target VEGF receptors rather than the VEGFs)...
14 KB (1,671 words) - 23:17, 4 September 2024
the Stem Book. Examples are: -anib for angiogenesis inhibitors (e.g. pazopanib) -anserin for serotonin receptor antagonists, especially 5-HT2 antagonists...
17 KB (1,650 words) - 13:04, 18 June 2024
Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies:...
31 KB (3,430 words) - 05:24, 28 August 2024
Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies:...
149 KB (15,717 words) - 06:34, 13 August 2024
Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies:...
68 KB (5,999 words) - 20:41, 31 August 2024